MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why [Yahoo! Finance]
ADMA Biologics Inc (ADMA)
Last adma biologics inc earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.admabiologics.com
Company Research
Source: Yahoo! Finance
The company is progressing well with the development of its lead pipeline candidate MM120 (lysergide D-tartrate) for the treatment of generalized anxiety disorder (GAD). FDA granted a breakthrough therapy designation to MM120 for treating GAD last month. Also, last month, MNMD announced that the phase IIb MMED008 study, which evaluated a single oral dose of MM120 (100 µg) in GAD. The study met its key secondary endpoint by demonstrating clinically and statistically significant durability of activity seen through week 12 of treatment. The data showed that MM120 maintained a clinically and statistically significant Hamilton Anxiety rating scale (HAM-A) reduction as compared with placebo at 12 weeks of treatment. These were the factors driving the stock's rise in the said time frame. Image Source: Zacks Investment Research Previously, MM120 had demonstrated rapid, clinically meaningful and statistically significant improvement on HAM-A versus placebo at week four of treatmen
Show less
Read more
Impact Snapshot
Event Time:
ADMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADMA alerts
High impacting ADMA Biologics Inc news events
Weekly update
A roundup of the hottest topics
ADMA
News
- Adma Biologics (ADMA) Gains As Market Dips: What You Should Know [Yahoo! Finance]Yahoo! Finance
- ADMA Biologics, Inc. (NASDAQ: ADMA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock.MarketBeat
- Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- ADMA Biologics Set to Join S&P SmallCap 600 IndexGlobeNewswire
- Questor: How to turn blood into gold [Yahoo! Finance]Yahoo! Finance
ADMA
Earnings
- 8/8/24 - Beat
ADMA
Sec Filings
- 9/11/24 - Form 4
- 9/9/24 - Form 144
- 8/30/24 - Form 4
- ADMA's page on the SEC website